Scientists develop simple blood test for early detection of Alzheimer's disease

HKUST scientists develop simple blood test for early detection of Alzheimer's disease
HKUST's Vice-President (Research and Development) Prof. Nancy Ip (Middle) and her research team members—including doctoral student Mr. Jason Jiang Yuanbing (second left) who is the first author of this research paper. Credit: HKUST

An international research team led by HKUST has developed a simple but robust blood test from Chinese patient data for early detection and screening of Alzheimer's disease (AD) for the first time, with an accuracy level of over 96%.

Currently, doctors mainly rely on cognitive tests to diagnose a person with AD. Besides clinical assessment, brain imaging and lumbar puncture are the two most commonly used to detect changes in the brain caused by AD. However, these methods are expensive, invasive, and frequently unavailable in many countries.

Now, a team led by Prof. Nancy Ip, Vice-President for Research and Development at HKUST, has identified 19 out of the 429 associated with AD to form a biomarker panel representative of an "AD signature" in the blood. Based on this panel, the team has developed a that distinguishes AD patients from healthy people with more than 96% accuracy. This system can also differentiate among the early, intermediate, and late stages of AD, and can be used to monitor the progression of the disease over time. These exciting findings have led to the development of a high-performance, blood-based test for AD, and may also pave the way to novel therapeutic treatments for the disease.

HKUST scientists develop simple blood test for early detection of Alzheimer's disease
Using the blue device (pictured) that performs the ultrasensitive proximity extension assay technology, Prof. Ip and her team developed a blood test for early detection and screening of Alzheimer's disease from Chinese patient data, with an accuracy level of over 96%. Credit: HKUST

"With the advancement of ultrasensitive blood-based detection technology, we have developed a simple, noninvasive, and accurate diagnostic solution for AD, which will greatly facilitate population-scale screening and staging of the disease," said Prof. Nancy Ip, Morningside Professor of Life Science and the Director of the State Key Laboratory of Molecular Neuroscience at HKUST.

The work was conducted in collaboration with researchers at University College London and clinicians in local hospitals including the Prince of Wales Hospital and Queen Elizabeth Hospital. The discovery was made using the proximity extension assay (PEA)—a cutting-edge ultrasensitive and high-throughput protein measurement technology, to examine the levels of over 1,000 proteins in the plasma of AD patients in Hong Kong.

As the most comprehensive study of blood proteins in AD patients to date, the work has recently been published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, and has also been featured and actively discussed on different scholarly exchange platforms on AD research such as Alzforum.

AD, which affects over 50 million people worldwide, involves the dysfunction and loss of brain cells. Its symptoms include progressive memory loss as well as impaired movement, reasoning, and judgment. While patients often only seek medical attention and are diagnosed when they have memory problems, AD affects the brain at least 10 to 20 years before symptoms appear.

Explore further

Discovery of biomarker could help predict Alzheimer's years before symptoms emerge

More information: Yuanbing Jiang et al, Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging, Alzheimer's & Dementia (2021). DOI: 10.1002/alz.12369
Citation: Scientists develop simple blood test for early detection of Alzheimer's disease (2021, June 28) retrieved 26 September 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors